您好，欢迎来到试剂仪器网！ [登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > NBI-31772 hydrate
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
NBI-31772 hydrate
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
NBI-31772 hydrate图片
包装:5mg
市场价:4230元

产品介绍
NBI-31772hydrate是胰岛素样生长因子IGF与IGFBP相互作用的有效抑制剂。NBI-31772hydrate也是一种非肽类配体，可从其结合蛋白复合物IGF-I/IGFBP-3中释放生物活性IGF-I(对六种人类亚型的Ki=1-24nM)。具有抗焦虑和抗抑郁作用。
Canonical SMILESO=C(C1=CC(O)=C(O)C=C1)C2=NC(C(O)=O)=CC3=C2C=C(O)C(O)=C3.[7/4].O
分子式C17H11NO7.7/4H2O
分子量372.82
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

NBI-31772 hydrate is a potent inhibitor of interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs). NBI-31772 hydrate is also a nonpeptide ligand that releases bioactive IGF-I from the IGF-I/IGFBP-3 complex (Kis=1-24 nM for all six human subtypes). Anxiolytic and antidepressant-like effects[1][2][3].

NBI-31772 (5-100 μg; icv; immediately or at 1, 2, or, 3 hours after MCAO) at the time of ischemia onset also dose-dependently reduced infarct size, and the highest dose (100 μg) significantly reduced both total and cortical infarct volume[3]. Animal Model: Sprague-Dawley rats (subtemporal middle cerebral artery occlusion model, MCAO)[3]

[1]. Liu XJ, et al. Identification of a nonpeptide ligand that releases bioactive insulin-like growth factor-I from its binding protein complex. J Biol Chem. 2001 Aug 31;276(35):32419-22. [2]. De Ceuninck F, et al. Pharmacological disruption of insulin-like growth factor 1 binding to IGF-binding proteins restores anabolic responses in human osteoarthritic chondrocytes. Arthritis Res Ther. 2004;6(5):R393-403. [3]. Malberg JE, et al, Rosenzweig-Lipson S. Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology. 2007 Nov;32(11):2360-8.